Systems biology of pro‐angiogenic therapies targeting the VEGF system

Vascular endothelial growth factor (VEGF) is a family of cytokines for which the dysregulation of expression is involved in many diseases; for some, excess VEGF causes pathological hypervascularization, while for others VEGF‐induced vascular remodeling may alleviate ischemia and/or hypoxia. Anti‐angiogenic therapies attacking the VEGF pathway have begun to live up to their promise for treatment of certain cancers and of age‐related macular degeneration. However, the corollary is not yet true: in coronary artery disease and peripheral artery disease, clinical trials of pro‐angiogenic VEGF delivery have not, so far, proven successful. The VEGF and VEGF‐receptor system is complex, with at least five ligand genes, some encoding multiple protein isoforms and five receptor genes. A systems biology approach for designing pro‐angiogenic therapies, using a combination of quantitative experimental approaches and detailed computational models, is essential to deal with this complexity and to understand the effects of drugs targeting the system. This approach allows us to learn from unsuccessful clinical trials and to design and test novel single therapeutics or combinations of therapeutics. Among the parameters that can be varied in order to determine optimal strategy are dosage, timing of multiple doses, route of administration, and the molecular target. Copyright © 2010 John Wiley & Sons, Inc.

[1]  Aleksander S Popel,et al.  A computational model of intracellular oxygen sensing by hypoxia-inducible factor HIF1α , 2006, Journal of Cell Science.

[2]  D. Stewart,et al.  Angiogenic gene therapy in patients with nonrevascularizable ischemic heart disease: a phase 2 randomized, controlled trial of AdVEGF121 (AdVEGF121) versus maximum medical treatment , 2006, Gene Therapy.

[3]  Aleksander S. Popel,et al.  A Compartment Model of VEGF Distribution in Humans in the Presence of Soluble VEGF Receptor-1 Acting as a Ligand Trap , 2009, PloS one.

[4]  P. Lloyd,et al.  Angiogenic growth factor expression in rat skeletal muscle in response to exercise training. , 2003, American journal of physiology. Heart and circulatory physiology.

[5]  Frédéric Dayan,et al.  Gene regulation in response to graded hypoxia: the non-redundant roles of the oxygen sensors PHD and FIH in the HIF pathway. , 2009, Journal of theoretical biology.

[6]  C. Grines,et al.  Angiogenic Gene Therapy (AGENT) Trial in Patients With Stable Angina Pectoris , 2002, Circulation.

[7]  D. Cheresh,et al.  Definition of two angiogenic pathways by distinct alpha v integrins. , 1995, Science.

[8]  T. Henry,et al.  Pharmacological Treatment of Coronary Artery Disease With Recombinant Fibroblast Growth Factor-2: Double-Blind, Randomized, Controlled Clinical Trial , 2002, Circulation.

[9]  R. Hendel,et al.  Effect of intracoronary recombinant human vascular endothelial growth factor on myocardial perfusion: evidence for a dose-dependent effect. , 2000, Circulation.

[10]  Holger Gerhardt,et al.  VEGFRs and Notch: a dynamic collaboration in vascular patterning. , 2009, Biochemical Society transactions.

[11]  Lieve Moons,et al.  Abnormal blood vessel development and lethality in embryos lacking a single VEGF allele , 1996, Nature.

[12]  Aleksander S. Popel,et al.  Impaired Angiogenesis After Hindlimb Ischemia in Type 2 Diabetes Mellitus: Differential Regulation of Vascular Endothelial Growth Factor Receptor 1 and Soluble Vascular Endothelial Growth Factor Receptor 1 , 2007, Circulation research.

[13]  B. Lévy,et al.  Inhibition of Prolyl Hydroxylase Domain Proteins Promotes Therapeutic Revascularization , 2009, Circulation.

[14]  E. Rebar,et al.  Engineered Zinc Finger–Activating Vascular Endothelial Growth Factor Transcription Factor Plasmid DNA Induces Therapeutic Angiogenesis in Rabbits With Hindlimb Ischemia , 2004, Circulation.

[15]  Douglas Losordo,et al.  Therapeutic angiogenesis for critical limb ischemia: microvascular therapies coming of age. , 2008, Circulation.

[16]  G. Hughes,et al.  Angiogenic therapy for coronary artery and peripheral arterial disease , 2005, Expert review of cardiovascular therapy.

[17]  M. Simons,et al.  Growth factor-induced therapeutic angiogenesis in the heart: protein therapy. , 2005, Cardiovascular research.

[18]  S. Ylä-Herttuala,et al.  HIF-VEGF-VEGFR-2, TNF-alpha and IGF pathways are upregulated in critical human skeletal muscle ischemia as studied with DNA array. , 2004, Atherosclerosis.

[19]  M. Luisa Iruela-Arispe,et al.  Processing of VEGF-A by matrix metalloproteinases regulates bioavailability and vascular patterning in tumors , 2005, The Journal of cell biology.

[20]  Aleksander S Popel,et al.  Skeletal muscle VEGF gradients in peripheral arterial disease: simulations of rest and exercise. , 2007, American journal of physiology. Heart and circulatory physiology.

[21]  Aleksander S. Popel,et al.  Three autocrine feedback loops determine HIF1α expression in chronic hypoxia , 2007 .

[22]  D. Marchuk,et al.  A Quantitative Trait Locus (LSq-1) on Mouse Chromosome 7 Is Linked to the Absence of Tissue Loss After Surgical Hindlimb Ischemia , 2008, Circulation.

[23]  J. Ware,et al.  Therapeutic angiogenesis in cardiovascular disease , 2003, Nature Reviews Drug Discovery.

[24]  J. Lowe,et al.  Transmyocardial laser revascularization: experimental and clinical results. , 1999, The Canadian journal of cardiology.

[25]  Seng H. Cheng,et al.  A hypoxic inducible factor‐1α hybrid enhances collateral development and reduces vascular leakage in diabetic rats , 2009, The journal of gene medicine.

[26]  D J Mooney,et al.  Spatiotemporal control of vascular endothelial growth factor delivery from injectable hydrogels enhances angiogenesis , 2007, Journal of thrombosis and haemostasis : JTH.

[27]  P. D’Amore,et al.  Contextual role for angiopoietins and TGFβ1 in blood vessel stabilization , 2007, Journal of Cell Science.

[28]  John N Weinstein,et al.  Properties of switch-like bioregulatory networks studied by simulation of the hypoxia response control system. , 2004, Molecular biology of the cell.

[29]  J. Pearlman,et al.  Impact of Mouse Strain Differences in Innate Hindlimb Collateral Vasculature , 2005, Arteriosclerosis, thrombosis, and vascular biology.

[30]  S. Rajagopalan,et al.  Adenovirus-Mediated Gene Transfer of VEGF121 Improves Lower-Extremity Endothelial Function and Flow Reserve , 2001, Circulation.

[31]  M. Fruttiger.  VEGF Gene Regulation , 2008 .

[32]  David J. Mooney,et al.  Design of Biodegradable Hydrogel for the Local and Sustained Delivery of Angiogenic Plasmid DNA , 2008, Pharmaceutical Research.

[33]  G. Qing,et al.  Hypoxia inducible factor-2alpha: a critical mediator of aggressive tumor phenotypes. , 2009, Current opinion in genetics & development.

[34]  M. Ladomery,et al.  Alternative splicing in angiogenesis: the vascular endothelial growth factor paradigm. , 2007, Cancer letters.

[35]  S. Ibayashi,et al.  Krypton laser-induced photothrombotic distal middle cerebral artery occlusion without craniectomy in mice. , 2004, Brain research. Brain research protocols.

[36]  H. Haider,et al.  Therapeutic Angiogenesis for Treatment of Peripheral Vascular Disease , 2004, Growth factors.

[37]  C. Lau,et al.  Prospective randomized trial of direct endomyocardial implantation of bone marrow cells for treatment of severe coronary artery diseases (PROTECT-CAD trial). , 2007, European heart journal.

[38]  Lena Claesson-Welsh,et al.  Signal transduction by VEGF receptors in regulation of angiogenesis and lymphangiogenesis. , 2006, Experimental cell research.

[39]  Jörn Tongers,et al.  Human studies of angiogenic gene therapy. , 2009, Circulation research.

[40]  K. Alitalo,et al.  The FASEB Journal express article 10.1096/fj.05-3720fje. Published online June 15, 2005. , 2022 .

[41]  Aleksander S Popel,et al.  Three autocrine feedback loops determine HIF1 alpha expression in chronic hypoxia. , 2007, Biochimica et biophysica acta.

[42]  Christian Fischer,et al.  FLT1 and its ligands VEGFB and PlGF: drug targets for anti-angiogenic therapy? , 2008, Nature Reviews Cancer.

[43]  J C Schaff,et al.  Virtual Cell modelling and simulation software environment. , 2008, IET systems biology.

[44]  James T. Willerson,et al.  Transendocardial, Autologous Bone Marrow Cell Transplantation for Severe, Chronic Ischemic Heart Failure , 2003, Circulation.

[45]  T. Haas,et al.  Evolving strategies in manipulating VEGF/VEGFR signaling for the promotion of angiogenesis in ischemic muscle. , 2009, Current pharmaceutical design.

[46]  L. Claesson‐Welsh,et al.  VEGF receptor signalling ? in control of vascular function , 2006, Nature Reviews Molecular Cell Biology.

[47]  Robert Langer,et al.  Genetic engineering of human stem cells for enhanced angiogenesis using biodegradable polymeric nanoparticles , 2009, Proceedings of the National Academy of Sciences.

[48]  Aleksander S. Popel,et al.  A compartment model of VEGF distribution in blood, healthy and diseased tissues , 2008, BMC Systems Biology.

[49]  R. Hendel,et al.  Phase 1/2 Placebo-Controlled, Double-Blind, Dose-Escalating Trial of Myocardial Vascular Endothelial Growth Factor 2 Gene Transfer by Catheter Delivery in Patients With Chronic Myocardial Ischemia , 2002, Circulation.

[50]  P. Ratcliffe,et al.  Oxygen sensors and angiogenesis. , 2002, Seminars in cell & developmental biology.

[51]  M. Saint-Geniez,et al.  TGF-β Is Required for Vascular Barrier Function, Endothelial Survival and Homeostasis of the Adult Microvasculature , 2009, PloS one.

[52]  A. Smit,et al.  Treatment with intramuscular vascular endothelial growth factor gene compared with placebo for patients with diabetes mellitus and critical limb ischemia: a double-blind randomized trial. , 2006, Human Gene Therapy.

[53]  Yinghua Su,et al.  VEGF gene therapy fails to improve perfusion of ischemic myocardium in patients with advanced coronary disease: results of the NORTHERN trial. , 2009, Molecular therapy : the journal of the American Society of Gene Therapy.

[54]  Brian H Annex,et al.  Growth factors for therapeutic angiogenesis in peripheral arterial disease , 2007, Current opinion in cardiology.

[55]  D. Chung,et al.  Hypoxia-Inducible Factor-1-Independent Regulation of Vascular Endothelial Growth Factor by Hypoxia in Colon Cancer , 2004, Cancer Research.

[56]  Brian H Annex,et al.  Claudication of Vascular Endothelial Growth Factor 121 in Patients With Disabling Intermittent Disease : A Phase II Randomized , Double-Blind , Controlled Study of Adenoviral Delivery Regional Angiogenesis With Vascular Endothelial Growth Factor in Peripheral Arterial , 2003 .

[57]  R. Hendel,et al.  Intracoronary administration of recombinant human vascular endothelial growth factor to patients with coronary artery disease. , 2001, American heart journal.

[58]  J. Hartikainen,et al.  Safety and Feasibility of Catheter-Based Local Intracoronary Vascular Endothelial Growth Factor Gene Transfer in the Prevention of Postangioplasty and In-Stent Restenosis and in the Treatment of Chronic Myocardial Ischemia: Phase II Results of the Kuopio Angiogenesis Trial (KAT) , 2003, Circulation.

[59]  Kenneth J. Hillan,et al.  Heterozygous embryonic lethality induced by targeted inactivation of the VEGF gene , 1996, Nature.

[60]  B. Annex,et al.  In Mice With Type 2 Diabetes, a Vascular Endothelial Growth Factor (VEGF)-Activating Transcription Factor Modulates VEGF Signaling and Induces Therapeutic Angiogenesis After Hindlimb Ischemia , 2007, Diabetes.

[61]  Michael Hucka,et al.  SBMLToolbox: an SBML toolbox for MATLAB users , 2006, Bioinform..

[62]  F. Orsenigo,et al.  Vascular endothelial cadherin controls VEGFR-2 internalization and signaling from intracellular compartments , 2006, The Journal of cell biology.

[63]  S. Rajagopalan,et al.  Phase I study of direct administration of a replication deficient adenovirus vector containing the vascular endothelial growth factor cDNA (CI-1023) to patients with claudication. , 2002, The American journal of cardiology.

[64]  S. Ylä-Herttuala,et al.  Increased vascularity detected by digital subtraction angiography after VEGF gene transfer to human lower limb artery: a randomized, placebo-controlled, double-blinded phase II study. , 2002, Molecular therapy : the journal of the American Society of Gene Therapy.

[65]  Aleksander S. Popel,et al.  Multi-scale Computational Models of Pro-angiogenic Treatments in Peripheral Arterial Disease , 2007, Annals of Biomedical Engineering.

[66]  A. Popel,et al.  Interactions of VEGF isoforms with VEGFR-1, VEGFR-2, and neuropilin in vivo: a computational model of human skeletal muscle. , 2007, American journal of physiology. Heart and circulatory physiology.

[67]  Brian H Annex,et al.  Computational kinetic model of VEGF trapping by soluble VEGF receptor-1: effects of transendothelial and lymphatic macromolecular transport. , 2009, Physiological genomics.

[68]  Federica Boschetti,et al.  Synergy between interstitial flow and VEGF directs capillary morphogenesis in vitro through a gradient amplification mechanism. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[69]  R. Dowling,et al.  Transmyocardial revascularization: 5-year follow-up of a prospective, randomized multicenter trial. , 2004, The Annals of thoracic surgery.

[70]  James R Faeder,et al.  Rule-based modeling of biochemical systems with BioNetGen. , 2009, Methods in molecular biology.

[71]  David A. Cheresh,et al.  Definition of Two Angiogenic Pathways by Distinct αv Integrins , 1995, Science.

[72]  I. Kurnaz,et al.  An in silico model for HIF‐α regulation and hypoxia response in tumor cells , 2007 .

[73]  R. G. Mitchell,et al.  Plasma levels of soluble Tie2 and vascular endothelial growth factor distinguish critical limb ischemia from intermittent claudication in patients with peripheral arterial disease. , 2008, Journal of the American College of Cardiology.

[74]  Alexander V. Zhdanov,et al.  PGC-1α is coupled to HIF-1α-dependent gene expression by increasing mitochondrial oxygen consumption in skeletal muscle cells , 2009, Proceedings of the National Academy of Sciences.

[75]  Florence T. H. Wu,et al.  VEGF and soluble VEGF receptor-1 (sFlt-1) distributions in peripheral arterial disease: an in silico model. , 2010, American journal of physiology. Heart and circulatory physiology.

[76]  A.A. Qutub,et al.  Multiscale models of angiogenesis , 2009, IEEE Engineering in Medicine and Biology Magazine.

[77]  C. Lau,et al.  Comparative evaluation of long-term clinical efficacy with catheter-based percutaneous intramyocardial autologous bone marrow cell implantation versus laser myocardial revascularization in patients with severe coronary artery disease. , 2007, American heart journal.

[78]  F. M. Gabhann,et al.  Systems Biology of Vascular Endothelial Growth Factors , 2008, Microcirculation.

[79]  A. Majid,et al.  Differences in Vulnerability to Permanent Focal Cerebral Ischemia Among 3 Common Mouse Strains , 2000, Stroke.

[80]  D. Mooney,et al.  Promoting angiogenesis via manipulation of VEGF responsiveness with notch signaling. , 2009, Biomaterials.

[81]  Seppo Ylä-Herttuala,et al.  Vascular endothelial growth factors: biology and current status of clinical applications in cardiovascular medicine. , 2007, Journal of the American College of Cardiology.

[82]  Aleksander S. Popel,et al.  Reactive Oxygen Species Regulate Hypoxia-Inducible Factor 1α Differentially in Cancer and Ischemia , 2008, Molecular and Cellular Biology.

[83]  M. J. Thompson,et al.  Fiber type-specific differential expression of angiogenic factors in response to chronic hindlimb ischemia. , 2000, American journal of physiology. Heart and circulatory physiology.

[84]  Paul A. Bates,et al.  Tipping the Balance: Robustness of Tip Cell Selection, Migration and Fusion in Angiogenesis , 2009, PLoS Comput. Biol..

[85]  B. Spiegelman,et al.  HIF-independent regulation of VEGF and angiogenesis by the transcriptional coactivator PGC-1α , 2008, Nature.

[86]  David A. Schultz,et al.  A mechanosensory complex that mediates the endothelial cell response to fluid shear stress , 2005, Nature.

[87]  J. Aronowski,et al.  Perspectives on reperfusion-induced damage in rodent models of experimental focal ischemia and role of gamma-protein kinase C. , 2003, ILAR journal.

[88]  Jianhua Huang,et al.  A Role for VEGF as a Negative Regulator of Pericyte Function and Vessel Maturation , 2008, Nature.

[89]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[90]  Christoph Dehio,et al.  Role of PlGF in the intra- and intermolecular cross talk between the VEGF receptors Flt1 and Flk1 , 2003, Nature Medicine.

[91]  M. Simon,et al.  Biology of hypoxia-inducible factor-2α in development and disease , 2008, Cell Death and Differentiation.

[92]  J. Isner,et al.  Lower-Extremity Edema Associated with Gene Transfer of Naked DNA Encoding Vascular Endothelial Growth Factor , 2000, Annals of Internal Medicine.

[93]  Masaru Tomita,et al.  E-Cell 2: Multi-platform E-Cell simulation system , 2003, Bioinform..

[94]  Craig Pratt,et al.  A randomized, double-blind, placebo-controlled trial of Ad5FGF-4 gene therapy and its effect on myocardial perfusion in patients with stable angina. , 2003, Journal of the American College of Cardiology.

[95]  A. Nagy,et al.  Embryonic development is disrupted by modest increases in vascular endothelial growth factor gene expression. , 2000, Development.

[96]  H. Blau,et al.  Microenvironmental VEGF concentration, not total dose, determines a threshold between normal and aberrant angiogenesis. , 2004, The Journal of clinical investigation.

[97]  Aleksander S Popel,et al.  VEGF gradients, receptor activation, and sprout guidance in resting and exercising skeletal muscle. , 2007, Journal of applied physiology.

[98]  H. Bøtker,et al.  Direct intramyocardial plasmid vascular endothelial growth factor-A165 gene therapy in patients with stable severe angina pectoris A randomized double-blind placebo-controlled study: the Euroinject One trial. , 2005, Journal of the American College of Cardiology.

[99]  H. Dvorak,et al.  Why are tumour blood vessels abnormal and why is it important to know? , 2009, British Journal of Cancer.

[100]  A. Popel,et al.  Model of competitive binding of vascular endothelial growth factor and placental growth factor to VEGF receptors on endothelial cells. , 2004, American journal of physiology. Heart and circulatory physiology.

[101]  K Walsh,et al.  Constitutive expression of phVEGF165 after intramuscular gene transfer promotes collateral vessel development in patients with critical limb ischemia. , 1998, Circulation.

[102]  Brian H Annex,et al.  The VIVA Trial Vascular Endothelial Growth Factor in Ischemia for Vascular Angiogenesis , 2003 .

[103]  D. Mozaffarian,et al.  Heart disease and stroke statistics--2009 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. , 2009, Circulation.

[104]  D. Pomp,et al.  Collateral density, remodeling, and VEGF-A expression differ widely between mouse strains. , 2007, Physiological genomics.

[105]  G. Semenza,et al.  Purification and Characterization of Hypoxia-inducible Factor 1 (*) , 1995, The Journal of Biological Chemistry.

[106]  Y. Huang,et al.  An engineered VEGF‐activating zinc finger protein transcription factor improves blood flow and limb salvage in advanced‐age mice , 2006, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.